Milestone Pharmaceuticals Inc. (MIST) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1111 Dr. Frederik-Philips Boulevard
Montreal, QC H4M 2X6
Canada
Phone
15143360444
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
May 09, 2019
| Name | Title | Pay | Year Born |
| Joseph G. Oliveto | Chief Executive Officer, President & Director | 931,384 | 1968 |
| Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development | 631,860 | 1973 |
| David Bharucha FACC | Chief Medical Officer | 664,417 | 1962 |
| Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board | 0 | 1962 |
| Guy Rousseau | SVP of Regulatory Affairs and Quality Management | 0 | N/A |
| Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board | 0 | 1956 |
| Jeff Moore | Vice President of Sales | 0 | N/A |
| Jeff Nelson | Chief Operating Officer | 0 | 1981 |
| Roshan Girglani | Vice President of Marketing | 0 | N/A |
| David Sandoval | General Counsel & Chief Compliance Officer | 0 | 1978 |
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.